This is a biomarker-driven trial that will enroll patients with recurrent or metastatic
squamous cell carcinoma of the head and neck progressing after first-line platinum-based
chemotherapy. Based on potential biomarkers and molecular alterations identified in the
biopsy from the central platform, patients will be allocated in different cohorts. There will
be biomarker-positive patient cohorts and immunotherapy cohorts.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC